Articles Tagged With:
-
Nalmefene Injection (Zurnal) and Intranasal Nalmefene HCl (Opvee)
The U.S. Food and Drug Administration has approved the first nalmefene autoinjector for the emergency treatment of known or suspected opioid overdose. Nalmefene is an opioid antagonist and an analog of naltrexone. It was granted a priority review and accelerated approval with a breakthrough therapy designation. It is distributed by Purdue Pharma L.P. as Zurnal.
-
A Review of HIV Pre-Exposure Prophylaxis
Human immunodeficiency virus (HIV) pre-exposure prophylaxis is a tool for preventing HIV, especially among high-risk populations. Three medication options are available. Regular screening for HIV and sexually transmitted infections is required, and adherence is crucial for effectiveness. PrEP is underused but increasingly covered by insurance, offering an important preventive option in sexual healthcare.
-
Clarifying the Risk of Aortic Aneurysm Development
A large, cross-sectional study of adults by aortic computed tomography angiography has shown that aortic aneurysms (AAs) are more frequent in men than women. While increasing age and body surface area were common risk factors for AA, hypertension was associated with thoracic AA, and hypercholesterolemia and smoking were risk factors for abdominal AA.
-
Poor Diabetes Control Associated with Poorer Coronary Stent Outcomes
In this large, observational study of diabetic patients with coronary stents, poorer glycemic control as measured by hemoglobin A1c was associated with stepwise hazard for stent failure over a period of more than six years, primarily driven by in-stent restenosis.
-
Does Semaglutide Protect Against Adverse Effects from COVID-19?
Semaglutide recipients who developed COVID-19 had significant protection against the occurrence of adverse outcomes, including death.
-
Providers Need to Know if Patients Are Receiving Ketamine Treatments
OB/GYNs and other reproductive healthcare providers need to find out during contraceptive and pregnancy counseling whether their patients are using or have plans to use ketamine, a drug that is becoming more common for use among psychiatric patients, new research says.
-
The Factors Affecting How Women Access Reproductive Healthcare in Appalachia
Women living in small, rural communities tied together by religion and social traditions may have difficulty accessing their preferred contraception because of both social barriers and having fewer reproductive healthcare providers near their homes.
-
Ohio Offers Case Study on How Abortion Laws Affect Providers and Patients
Since the U.S. Supreme Court overturned Roe v. Wade, many states have changed their laws about abortion care — sometimes making three or more changes over the past couple of years. This has resulted in abortion providers and clinics having to make quick changes in policies and which patients they will accept.
-
Medicaid Rules May Hinder Receiving Permanent Contraception Postpartum
People giving birth while receiving Medicaid have 56% lower odds of obtaining postpartum sterilization than people who gave birth while on private insurance, a new study shows.
-
Up to 1 in 20 People Can Get Pregnant After Tubal Sterilization Procedure
Permanent contraception may not be as permanent as people think. New research shows the challenges physicians have when providing contraceptive counseling to patients who do not want to be pregnant now or in the future.